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Molkov YI, Zaretskaia MV, Zaretsky DV. Meth math: modeling
temperature responses to methamphetamine. Am J Physiol Regul
Integr Comp Physiol 306: R552–R566, 2014. First published Febru-
ary 5, 2014; doi:10.1152/ajpregu.00365.2013.—Methamphetamine
(Meth) can evoke extreme hyperthermia, which correlates with neu-
rotoxicity and death in laboratory animals and humans. The objective
of this study was to uncover the mechanisms of a complex dose
dependence of temperature responses to Meth by mathematical mod-
eling of the neuronal circuitry. On the basis of previous studies, we
composed an artificial neural network with the core comprising three
sequentially connected nodes: excitatory, medullary, and sympathetic
preganglionic neuronal (SPN). Meth directly stimulated the excitatory
node, an inhibitory drive targeted the medullary node, and, in high
doses, an additional excitatory drive affected the SPN node. All model
parameters (weights of connections, sensitivities, and time constants)
were subject to fitting experimental time series of temperature re-
sponses to 1, 3, 5, and 10 mg/kg Meth. Modeling suggested that the
temperature response to the lowest dose of Meth, which caused an
immediate and short hyperthermia, involves neuronal excitation at a
supramedullary level. The delay in response after the intermediate
doses of Meth is a result of neuronal inhibition at the medullary level.
Finally, the rapid and robust increase in body temperature induced by
the highest dose of Meth involves activation of high-dose excitatory
drive. The impairment in the inhibitory mechanism can provoke a
life-threatening temperature rise and makes it a plausible cause of
fatal hyperthermia in Meth users. We expect that studying putative
neuronal sites of Meth action and the neuromediators involved in a
detailed model of this system may lead to more effective strategies for
prevention and treatment of hyperthermia induced by amphetamine-
like stimulants.
amphetamines; artificial neural network; body temperature; hyperther-
mia; modeling
DERIVATIVES OF AMPHETAMINES are widely abused all over the
world. After long-term use, cognitive, neurophysiological, and
neuroanatomic deficits have been reported (10, 11, 47, 62, 66,
69, 75). Neurophysiological deficits are enhanced by hyper-
thermia (2), which is a major mortality factor in drug abusers
(27, 74). Despite numerous studies investigating the mecha-
nisms underlying methamphetamine (Meth)-induced hyper-
thermia, there are no specific treatments. A key barrier to the
design of specific treatments is a lack of consensus regarding
which brain regions and receptors are involved.
Meth has a complicated dose-related temperature response.
Relatively low doses of Meth (1 mg/kg) cause a short-lived,
but rapid, increase in body temperature (49, 59). As the dose of
Meth increases, the dose-response curve is not linear. Rather,
at 1–5 mg/kg Meth, peak temperatures do not increase, but the
time at which temperature peaks progressively shifts to the
right; for example, the peak temperature for 1 mg/kg Meth
(38°C) occurs at 60 min, while the peak temperature for 5
mg/kg Meth (38°C) occurs at 180 min. At 10 mg/kg Meth,
temperature once again rises rapidly, peaks at 60–90 min,
decreases slightly, and then rises again and remains elevated at
5 h (49).
Importantly, temperature responses to injections of Meth are
dependent on ambient temperature and may include hypother-
mic and hyperthermic phases (38). Similar complex tempera-
ture responses have been reported with other amphetamines,
including the substituted amphetamine 3,4-methylenedioxy-
methamphetamine (MDMA) (56).
Collectively, these responses point out the complex pharma-
cology of amphetamines and, in particular, Meth. Meth in-
creases multiple neurotransmitters, including dopamine, nor-
epinephrine, acetylcholine, glutamate, and serotonin (32, 53,
72). Meth can also act directly on -opioid receptors (41) and
trace amine receptors (78). Because of the multiple interactions
between these neurotransmitters and receptors, it is difficult to
study and understand the mechanisms underlying the temper-
ature effects of Meth. Further complicating the analysis, body
temperature is dependent on multiple thermoregulatory mech-
anisms and complex neuronal circuitry.
As acute complications (including fatalities) and chronic
neurotoxicity from Meth are linked to its effects on tempera-
ture (2, 31), a better understanding of how Meth affects body
temperature may provide insight into prevention and treatment
of these effects.
When administered in low doses, amphetamines, in general,
and Meth, in particular, induce an array of responses strikingly
similar to those evoked by stimulation or disinhibition of
neurons in the region of the dorsomedial hypothalamus (DMH)
in conscious rats: tachycardia, mild hypertension, hyperthermia
via an increase in thermogenesis and suppression of heat
dissipation, and activation of locomotion [see Refs. 14, 51, 65,
68, and 81 (DMH) and 38, 48, and 58 (amphetamines)]. In
turn, inhibition of the DMH with microinjections of muscimol
significantly attenuated hyperthermia, tachycardia, hyperten-
sion, and locomotion evoked by a systemic dose of MDMA
(58). The structural similarity between MDMA and Meth
allows us to hypothesize that the DMH may also be involved
in mediating responses to Meth.
In the past decade, DMH has emerged as a key hypothalamic
effector region, the activation of which plays an important role
in generating fever and stress responses (for reviews see Refs.
15–17, 22, and 77). The DMH exerts most of its autonomic
effects through medullary structures: the rostral ventrolateral
medulla (RVLM) (21) and ventromedial medulla (VMM) (7, 9,
63). Peripheral responses mediated by the DMH, including
thermoregulatory responses, are predominantly transmitted
through the raphe pallidus (RP) in the VMM. Among those
effects are nonshivering thermogenesis, including thermogen-
esis in the interscapular brown adipose tissue (7, 81), shivering,
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which can result in production of a significant amount of heat
(6, 39), and control of heat dissipation through cutaneous blood
flow (43, 44).
The sources of input to the DMH are multiple (42, 70);
however, their functional roles and relative importance in
mediating specific components of thermoregulatory processes
have not been described. Inhibition of the DMH can suppress
responses to activation of the amygdala (67) and dorsolateral
periaqueductal gray (PAG) (13). Stimulation of the amygda-
loid region affects cutaneous blood flow (36), which is a major
part of the thermoregulatory process. Whether those connec-
tions are direct and involved in mediation of stress, fever, or
responses to drugs of abuse remains unknown. Therefore, we
have described Meth as acting directly on the DMH, while it is
possible that this is not the case.
Our experimental data contained clear evidence of the pres-
ence of the inhibitory drive (the response to the intermediate
dose is weaker than the response to the low dose). The DMH
and RP have inhibitory inputs: disinhibition of both areas by
antagonists of GABAA receptors evokes thermogenic re-
sponses (37, 81) and a decrease in heat dissipation via con-
striction of the cutaneous vasculature (43). One of the main
sources of GABAergic projections to both areas is located in
the preoptic area; however, the cells projecting to each area are
not the same (40, 79). Inhibitory tone to the RP could also
originate from the ventrolateral PAG (52) and RVLM (8).
However, while the inhibitory component of responses to Meth
could be due to activation of the inhibitory projection (presyn-
aptic effect), it can also be mediated by activation of dopamine
(most likely D2) receptors (45, 55) or 2-adrenergic receptors
(34) located directly on neurons (postsynaptic effect). Without
experimental support for any specific pathway or receptor
involved, for clarity of description, we modeled our inhibitory
component as an inhibitory drive to the RP.
Finally (46), we demonstrated that 5-HT2A receptors in the
spinal cord contribute to cutaneous vasoconstriction after a
high dose of MDMA. The high-dose component is clearly
present in our data: a high dose of Meth overrides the inhibi-
tion, and body temperature rises sharply and remains elevated
for a long period of time.
Previous studies pinpoint a few brain areas possibly in-
volved in mediating the responses to Meth; however, in the
following description, we avoid specific locations, as they have
not been verified experimentally but, rather, rely on generic
descriptors of nodes (Fig. 1). We refer to the DMH as the
excitatory (Exc) node, and projection of the Exc to the med-
ullary (Mdl) node will compete for activation of the Mdl node
with the aggregate inhibitory drive, which is coming from the
inhibitory (Inhib) node. The high-dose (HD) component, which
cannot be inhibited by the inhibitory drive, enters the thermo-
genic pathway at the inframedullary sympathetic preganglionic
neuron (SPN) node.
Through an iterative process, we were able to create various
neural networks, each of which closely models observed tem-
perature responses from a range of Meth doses. Although they
are obviously different from each other, these networks share a
few core principles of organization, the most important of
which is competition between converging excitatory and in-
hibitory drives.
METHODS
Experimental Procedures
All procedures were approved by the Indiana University Institu-
tional Animal Care and Use Committee and followed National Insti-
tutes of Health guidelines.
Animal model. Male Sprague-Dawley rats (280–350 g body wt)
were individually housed with a 12:12-h light-dark cycle at a room
temperature of 23–25°C; the animals had free access to food and
water. All animals for which data are reported remained in good
health throughout the course of surgical procedures and experimental
protocols, as assessed by appearance, behavior, and maintenance of
body weight.
Surgical procedures. For measurements of core temperature, as
well as heart rate and blood pressure, telemetric transmitters (model
C50-PXT, Data Sciences International, St. Paul, MN) were implanted
under isoflurane anesthesia, as previously described (82). A catheter
was inserted into the abdominal aorta through the femoral artery, and
the body of the transmitter was placed into the abdominal cavity and
sutured to the abdominal wall. After 7 days of recovery, rats, still in
their home cages, were brought to the experimental room. The cages
were placed on telemetry receivers (model RPC-1, Data Sciences
International), and the animals were given 2 h to adapt to the new
environment.
Drugs. Methamphetamine hydrochloride was obtained from Sigma-
Aldrich (St. Louis, MO). It was dissolved in sterile saline at the time
of injections and injected at a volume of 1 ml/kg.
Fig. 1. Neuronal circuitry involved in re-
sponses to amphetamines. A: actual anatomic
structures. B: simplified conceptual network.
Lines with arrows, excitatory projections
(source is white); lines with circles, inhibitory
projections (source is gray). MPOA, medial
preoptic area; vlPAG and dlPAG, ventrolateral
and dorsolateral periaqueductal gray; RVLM,
rostral ventrolateral medulla; DMH, dorsome-
dial hypothalamus; RP, raphe pallidus; SC,
superior colliculus.
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Determining Temperature Responses to Meth
The temperature response to various doses of Meth was determined
by randomization of animals receiving an intraperitoneal injection of
saline or one of the four doses of Meth (1, 3, 5, or 10 mg/kg). Each
animal received only one injection, with six rats per dose. Data were
recorded every 2 min and transferred to Microsoft Excel, and 10-min
averages were calculated using a template in Excel.
Statistical Analysis
Values are means  SE. Data were compared using a one-way
ANOVA with repeated measures followed by Fisher’s least signifi-
cant difference post hoc test, where appropriate. P  0.05 was
considered to indicate a significant difference in all comparisons.
Baseline levels of activity, temperature, heart rate, and mean blood
pressure did not differ between groups across the series of experi-
ments, so changes from baseline were analyzed.
Model Construction
Three components were considered in constructing our model: 1)
the pharmacokinetic time course of Meth concentration in the blood
after an intraperitoneal injection, 2) a neural network, the activity of
which depends on Meth concentration in the blood, and 3) a temper-
ature control system that is driven by a signal from the neural
component.
Pharmacokinetics. Meth is rapidly absorbed from the peritoneum
and then eliminated from the blood with a profile closely resembling
a single-exponential process (23, 76). Our data do not contain inde-
pendent information about the volume of distribution. Therefore, we
have expressed the concentration in units of dose (mg/kg), and drug
concentrations are described in the model by the following equations
dx
dt

x
a
dy
dt

x
a

y
e
(1)
where t is time (in min), x(t) and y(t) are intraperitoneal and blood
Meth concentrations, respectively, x/a describes drug absorption with
a time constant a, and y/e represents drug elimination with a time
constant e. Initial conditions are x(0) 	 D,y(0), given that a dose D
is injected at time 0 (t 	 0). With these initial conditions, the solution
of Eq. 1 can be explicitly found as
y(t) D(a ⁄ e  1)1(et⁄a  et⁄e) (2)
which provides the Meth concentration in the blood at any given time.
Neural network. The network schematic used in our model is based
on previous research (see above) showing that neural populations in
three key interconnected brain regions are responsible for normal
rodent thermoregulation: excitatory drive is coming through the DMH
to premotor sympathetic neurons in the VMM (Mdl node) and is
relayed from the medulla to sympathetic preganglionic neurons in the
spinal cord (SPN node). Activation of the SPN node results in an
increase in body temperature via several mechanisms. In addition, we
know from our data and data of others that temperature responses to
amphetamines do not follow simple linear dose responses (35, 38, 46,
49, 59, 60). This can be seen in Fig. 2, where a low dose of Meth
causes acute increases in temperature that are greater than increases
caused by the two intermediate doses but lower than increases caused
by the highest dose. Therefore, the excitation in the model can be
suppressed by inhibitory drive, originating from supramedullary (pre-
optic nucleus or ventrolateral PAG) or intramedullary (RVLM) struc-
tures. We also know from the work of others that, at high doses, some
amphetamines appear to act below the level of the medulla (46). For
simplicity, our initial model factored in this postulated inframedullary
effect by creating an additional Exc node that, as we hypothesized,
would be activated only by higher doses of Meth (hence, the HD
node).
This circuitry is depicted in Fig. 3A. The model takes the form of
a feedforward artificial neural network. The outputs of “Meth-sensi-
tive” supramedullary excitatory (Exc), inhibitory (Inhib), and high-
dose-activated (HD) neural populations Pi (i 	 Exc, Inhib, and HD)
were calculated using the following formula
Pi(t) [wi · y(t) 	i] (3)
where (x) 	 (1 
 tanhx)/2 is a sigmoidal activation function, wi is
a parameter of sensitivity to Meth, y(t) is the time dependence of the
Meth concentration in the blood from Eq. 2, and i defines basal
excitability of Pi. Accordingly, the unit of sensitivity (wExc, wInhib,
and wHD) is (mg/kg)1 and Exc, Inhib, and HD are dimensionless.
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Fig. 2. Dose dependence of temperature responses
to methamphetamine (Meth). Meth was injected
intraperitoneally at 0 min (t 	 0) in a volume of
1 ml/kg.
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The activity of the Mdl was described as
PMdl(t) wExc¡Mdl · PExc(t) wInhib¡Mdl · PInhib(t) (4)
where wExc¡Mdl is the weight of the excitatory projection from Exc to
Mdl and wInhib¡Mdl is the weight of the inhibitory projection from
Inhib to Mdl. SPN then transmits the activity of Mdl, taking into
account the additional contribution of the Meth-sensitive (HD) node
PSPN(t) PMdlt wHD¡SPN · PHD(t) 	SPN (5)
where wHD¡SPN is the weight of the excitatory projection from HD to
SPN and SPN defines the basal excitability of the SPN neuronal node.
Temperature control. The temperature response is modeled by a
first-order linear ordinary differential equation and is driven by the
SPN signal as follows
T
dT
dt
 PSPN(t) (T T0) (6)
where T is body temperature (°C), T is a time constant of the
temperature response, and T0 is the baseline body temperature. By
design, activities of the Mdl and SPN nodes are measured in °C, as are
the synaptic weights wExc¡Mdl, wInhib¡Mdl, and wHD¡SPN.
We make two major assumptions when we use Eq. 6 to describe
temperature dynamics. Two terms of Eq. 6 represent heat production
and heat dissipation, respectively. Heat dissipation occurs because of
the difference between body temperature and environmental temper-
ature. Accordingly, the dissipation term has to be proportional to the
difference in the body and ambient temperatures and to the thermal
conductivity of the skin. The latter is inversely proportional to T in
Eq. 6. Thermal conductivity is dependent on cutaneous blood flow,
which can be regulated by cutaneous vasodilation to increase thermal
conductivity in response to the temperature increase. At room tem-
perature, the peripheral vessels are fully constricted, and sympatho-
mimetic effects of Meth through central and peripheral neuronal
mechanisms (3, 4, 58) will counteract effects of potential feedback
caused by hyperthermia. So, our first assumption is that T remains
constant throughout all simulations. The physiological implication is
that there is no afferent feedback through cutaneous vasodilation to
the system. Our second assumption is that basal body temperature is
an equilibrium temperature associated with basal metabolism and
cannot be lowered by any feedback mechanisms related to hyperther-
mia. It is possible to make this assumption, since we model the system
at room temperature; at room temperature, little additional heat is
produced or few heat dissipation mechanisms are engaged at baseline
due to close proximity to thermoneutrality.
Model parameter estimation. To determine the optimal values of
the model parameters to fit the experimental data, we minimized a cost
function, which consisted of a residual sum of squares E() and a
regularization term R()

() E() R() (7)
where 	 u, d, T, Exc, wExc, Inhib, wInhib, wExc¡Mdl, wInhib¡Mdl,
HD, wHD, SPN, and wHD¡SPN is the set of 13 parameters subject to
optimization. We used the Broyden-Fletcher-Goldfarb-Shanno method (a
multidimensional variable metric method) for minimization (50).
We had experimental time series of temperature responses to four
doses of Meth [Tk(tl)]{l 	 1n, k 	 1,4}, which were calculated from
original data (10-min averages; see above). We used the residual sum
of squares in the form
E()k14 l1n T(, dk, tl) Tk(tl)2 (8)
where T(,dk,tl) is the model’s temperature response calculated by
Eq. 6 at time tl for the dose of Meth D 	 dk for a particular set of
parameter values .
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Fig. 3. “Three-arrow” (circuitry-based) model. A: model schematic. Each circle represents a neural population. Meth-sensitive populations (“Meth”-labeled
arrows) are modeled as an artificial neuron with sigmoidal activation function applied to its input (see text for a detailed description). Circuitry is a compilation
of data from the literature. Exc, excitatory; Inhib, inhibitory; HD, high dose; Mdl, medulla; SPN, sympathetic preganglionic (or premotor) neuron; TEMP,
temperature. B: activation functions of Meth-sensitive populations. Vertical lines show half-activation concentrations. C: reconstructed activity of neuronal
populations included in the model, together with comparison of reconstructed dynamics of body temperature, after various doses of Meth, with actual
experimental data used in fitting procedures. All reconstructed values of body temperature were within 1 SD of actual experimental data within the time period
used for fitting procedures (220 min, gray bar). au, Arbitrary units.
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The minimization of Eq. 5 is an ill-posed problem, because the
model output depends mostly on the difference between Exc and Inhib
projections to Mdl, and not on their absolute values. In addition,
relatively low doses of Meth saturate Exc and Inhib activation.
Therefore, the model output is weakly dependent on the sensitivity
of these populations to Meth wExc and wInhib when their values are
large. To overcome these difficulties, we used the Tikhonov regular-
ization technique (71) by adding a regularization term
R() (wExc2  wInhib2  	PSN2  wExc¡Mdl2  wInhib¡Mdl2 ) (9)
to the cost function (7). To determine an optimal value of the
regularization factor , we used the L-curve method (24).
Model Reduction and Analysis
The original model was constructed on the basis of the hypothetical
thermoregulatory circuitry available in the literature and had three
Meth-sensitive nodes. Subsequent analysis of the model revealed
several features redundant from a data assimilation perspective. Spe-
cifically, the experimentally observed temperature curves could be
reproduced with comparable precision by use of the reduced circuit-
ries receiving two or even one Meth-dependent input. Hereafter, we
refer to these three models as the “three-arrow,” “two-arrow,” and
“one-arrow” models, respectively.
Two-arrow model. In our initial three-arrow model, we incorpo-
rated an inframedullary excitatory input that was activated only at
high doses of Meth. While our decision was based, in part, on intuition
and, in part, on previous data with MDMA (46), we also recognized
that a more parsimonious model might be sufficient and would
simplify its use. To test this, we derived a two-arrow model (see Fig.
5) from the original three-arrow model by setting wHD¡SPN 	 0. This
also had the effect of eliminating the parameters that described
activation of the HD population, HD and wHD, resulting in the need
to estimate only 10 parameters. This is possible from a conceptual
standpoint, because elimination of the HD component essentially
makes the inframedullary output directly dependent on the medullary
output and, thereby, redundant for modeling purposes. Essentially,
Mdl and SPN nodes were merged into a single SPN node; depending
on the location, SPN can mean “sympathetic premotor neurons” (for
the medullary location) or “sympathetic preganglionic neurons” (for
the spinal cord location).
One-arrow model. After confirming that the two-arrow model
(without the HD and Mdl nodes) also accurately fit the observed data,
we sought to simplify this model further. In the one-arrow model, only
Exc is sensitive to Meth, and Inhib is now activated by projection
from the Exc node (Fig. 6A). In this model, the activity of Inhib was
described as follows
PInhib(t) wExc¡Inhib · PExc(t) 	Inhib (10)
where wExc¡Inhib was the weight of the excitatory projection from Exc to
Inhib. This parameter replaced the sensitivity of Inhib to Meth (wInhib).
However, since the parameters of sensitivity of Inhib to Meth are replaced by
parameters of sensitivity to descending excitatory input, the total number of
parameters did not change compared with the two-arrow model.
Variability of temperature responses. To mimic experimentally
observed animal-to-animal variability, we constructed model re-
sponses with varied model parameters. For every model parameter i,
we calculated the average sensitivity of the temperature to the relative
parameter variation as
Si max t[0,L]
T(, D, t)
i
i (11)
where L 	 220 min is the time interval used, the dose of Meth (D) 	 10
mg/kg, and T/i is a partial derivative of the temperature at time t
with respect to i. We compared the calculated sensitivities and found
that, for all three models, the calculated temperatures had the greatest
sensitivity to variations in synaptic weights of the projections from
Exc and Inhib nodes to Mdl. In addition, the three-arrow model has a
comparable sensitivity to synaptic weight of the projection from HD
to SPN. Accordingly, we chose wExc¡Mdl, wInhib¡Mdl, and wHD¡SPN
as our control parameters for this analysis. Given the relative param-
eter variation , we multiplied wExc¡Mdl (and wHD¡SPN for the
3-arrow model) and divided wInhib¡Mdl by a factor of (1 
 ) to
generate the greatest possible temperature response and the same
parameters by a factor of (1  ) to obtain the lowest possible
temperature response.
We have also considered situations when the inhibitory drive is
significantly suppressed. For three- and two-arrow models, we have
generated the model curves of the body temperature with all parameters
being the same as in Table 1 but with wInhib¡Mdl equal to 0 or one-half
of its value in Table 1. The curves representing model responses to 1 and
3 mg/kg Meth in such situations are shown in Fig. 8.
RESULTS
Temperature Responses to Meth
The doses of Meth (1, 3, 5, and 10 mg/kg) used in this study
caused complex temperature responses (Fig. 2). At the lowest
dose (1 mg/kg), temperature rose almost immediately after the
injection, reached a peak (1°C above baseline) by 80 min, and
retuned to baseline within 3 h. Increasing the Meth dose to 3
mg/kg delayed the response: temperature started to rise 40 min
after the injection and peaked (also 1°C above baseline) at
150 min. Hyperthermia lasted for 4 h after 3 mg/kg Meth.
Similar to the low dose of Meth (1 mg/kg), 5 mg/kg Meth
increased body temperature immediately after injection. The
peak, however, was smaller (0.5°C) and occurred within 30
min. Temperature remained relatively constant for1 h, began
to rise again to a second peak (0.8°C above baseline) at 190
min, and, finally, returned to baseline within 4 h. Late phases
of temperature responses to intermediate doses (t  50 min for
3 mg/kg and t  90 min for 5 mg/kg) were similar to the
response to a low dose of Meth to the accuracy of a time shift.
Similar to 5 mg/kg Meth, the highest dose of Meth (10
mg/kg) caused an immediate increase in temperature. The
increase, however, was greater (2°C above baseline) and
required a longer period of time to peak (80 min). After
reaching a peak, the temperature fell over the next 60 min and
then, similar to the 5 mg/kg dose, peaked again, at least in
some animals, or remained relatively constant for 60 min. In
contrast to 5 mg/kg Meth, the second peak was not strongly
expressed, and temperature slowly returned to baseline levels
6 h after injection (data not shown).
Collectively, these data show a complex multimodal tem-
perature response to Meth that is highly dependent on the dose.
Estimated Parameters and Model Validation
Data shown in Fig. 2 were used to find the optimal set of
parameters of each of the models, as described in METHODS. The
calculated parameter values with their SE estimates are listed
in Table 1. To evaluate the goodness of fit, we calculated the
coefficient of determination (R2, Table 2) for each model and
all doses. R2 can be treated as a fraction of the variance
explained by the models, with a range of 65–95% for different
doses and, on average, is 90% for all three models. We also
calculated the ratio of the root mean square of the model
residuals to the SDs of temperature responses over the group of
animals (n 	 6). These calculations are shown in Table 3 for
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all three models and all doses. Because, in all cases, this
measure is much less than 100%, the model mismatch is well
within experimentally observed animal-to-animal variability.
To validate the model, we used k-fold cross-validation. Four
temperature time series as a single data set were randomly
divided into eight sets of points of equal size. Every set out of
eight was used for validation, and the remaining seven sets
were used to optimize the model parameters. The residuals for
the validation sets were collected and root-mean-squared to be
compared with the root-mean-square residuals for the training
sets. The ratios of root-mean-squared residuals for the valida-
tion and training sets were 1.12 for the three-arrow model, 1.08
for the two-arrow model, and 1.09 for the one-arrow model.
These ratios can be compared with the expected ratios in the
case of linear regression. Each training set comprised 77 data
points (n 	 77). The models had 13, 10, and 10 parameters
(p 	 13, 10, and 10), respectively. Accordingly, the expected
ratios of root-mean-squared residuals of validation and training
sets, r 	 np⁄np, were 1.18, 1.14, and 1.14. The
values obtained were slightly less than the estimates, probably
because of regularization used in our optimization procedure.
In general, it evidences the robustness of the models.
Model Simulation and Interpretation
These parameters were used to simulate the dynamics of
Meth concentration in the blood, activities of the neuronal
populations, and temperature responses to different doses of
Meth under various (patho)physiological conditions.
Pharmacokinetics. The dependence of Meth concentration
in the blood on time is described by Eq. 2, where a defines a
rate at which Meth is initially accumulated in the blood due to
its absorption from the peritoneum and e is responsible for the
rate at which the drug is washed out. After parameter optimi-
zation to fit experimental data in all models, absorption ap-
peared to be much faster than elimination (10 min vs. 60
min; see Table 1 for model-specific values). With such param-
eters, after an intraperitoneal injection of Meth, the blood
concentration quickly peaks at a maximum of 70% of the
dose and then exponentially decreases with a time constant
of 1 h.
Activity in the Meth-sensitive nodes in the three-arrow
model. In the three-arrow model, which was able to accurately
reproduce the observed temperature curves for all four doses of
Meth (Fig. 3C), three neuronal nodes were stimulated by Meth
directly (Fig. 3A): Exc, Inhib, and an excitatory projection to
the SPN node, which was activated only at high doses of Meth
(HD). The activation function of each Meth-sensitive popula-
tion depended on two parameters: half-activation concentration
and maximal slope. The slopes appeared to be comparable for
all nodes, while half-activation concentration was lowest for
Exc and highest for HD (Fig. 3B, Table 1, 3-arrow model).
Activation time courses of each of these nodes for each dose
of Meth are shown in Fig. 3C. All doses of Meth were able to
activate the Exc node, which reached 100% activity at 3 mg/kg
for a short period of time. Each successively higher dose
activated this node for a longer period of time. Similarly, the
Inhib node was activated by all doses of Meth. The sensitivity
of the Inhib node was less than that of the Exc node: the Inhib
node required higher doses of Meth for full activation and had
shorter durations of maximal activity at the higher doses.
Finally, the HD component was activated only at the two
highest doses of Meth (5 and 10 mg/kg).
Temperature responses to low and lower-intermediate
doses. The activity of the SPN, which defines an output of the
system, can be viewed as a competition between excitatory and
inhibitory drives. Excitatory drive in the three-arrow model is
a sum of drives from Exc and HD that is offset by activity of
the Inhib. To visualize how various doses of Meth result in
activity of the SPN, Fig. 4 presents the activation function for
combined excitatory drive and inhibitory drive (Fig. 4A)
matched with pharmacokinetic profiles of Meth at various
doses (Fig. 4C).
Table 1. Optimal model parameters with standard errors
Model
Parameter Three-arrow Two-arrow One-arrow
a, min 8.25  1.12 11.2  1.1 11.3  1.1
e, min 57.5  1.02 57.2  1.2 57.1  1.2
T, min 89.2  2.65 78.4  2.8 79.2  2.8
Exc, AU 0.357  0.006 0.437  0.002 0.376  0.005
wExc, (mg/kg)1 1.225  0.015 0.375  0.002 0.337  0.005
Exc/wExc,* mg/kg 0.29 1.17 1.12
Inhib, AU 1.335  0.013 1.746  0.008 4.27  0.01
wInhib, (mg/kg)1 1.463  0.017 1.140  0.007 N/A
Inhib/wInhib,* mg/kg 0.91 1.53 N/A
wExc¡Inhib, AU N/A N/A 7.47  0.02
HD, AU 3.69  0.05 N/A N/A
wHD, (mg/kg)1 0.872  0.013 N/A N/A
HD,* mg/kg 4.24 N/A N/A
SPN, °C 3.35  0.02 7.20  0.02 7.62  0.02
wExc¡Mdl, °C 9.89  0.03 N/A N/A
wInhib¡Mdl, °C 6.38  0.04 N/A N/A
wHD¡SPN, °C 5.66  0.12 N/A N/A
wExc¡SPN, °C N/A 24.86  0.04 23.82  0.04
wInhib¡SPN, °C N/A 12.12  0.05 10.44  0.05
Optimization was performed as described in Model parameter estimation in
methods. N/A, not applicable; , time constant; a, absorption; e, elimination; T,
temperature; , excitability; w, sensitivity; Exc, excitatory; Inhib, inhibitory;
HD, high dose; Mdl, medulla; SPN, sympathetic preganglionic (or premotor)
neuron. *Calculated half-activation Meth concentrations.
Table 2. Coefficient of determination as a measure of
goodness of fit
Meth Dose
Model 1 mg/kg 3 mg/kg 5 mg/kg 10 mg/kg Overall
Three-arrow 76.8 96.0 65.8 96.9 90.7
Two-arrow 66.9 95.4 64.4 94.7 87.8
One-arrow 65.9 94.9 63.8 94.8 87.6
Values are percentages. Goodness of fit is calculated as R2 	 1  Var(re-
siduals)/Var(average temperature).
Table 3. Model root-mean-square residual relative to the SD
of temperature over the group of animals root-mean-squared
over time of observation
Meth Dose
Model 1 mg/kg 3 mg/kg 5 mg/kg 10 mg/kg Overall
Three-arrow 41.9 17.7 55.7 17.4 29.0
Two-arrow 50.0 19.0 56.8 22.9 33.1
One-arrow 50.8 20.1 57.3 22.6 33.5
Values are percentages; n 	 6 for each group.
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At the lowest dose of Meth, Exc was the only activator of
SPN in the model (curve 1 in Fig. 4C), and inhibition from
Inhib was not sufficient to suppress excitation. Therefore, the
activity of the SPN population followed the activity of Exc.
At 3 mg/kg Meth, the inhibitory input from Inhib was able
to almost fully suppress the activity of the Mdl population,
which mediated an activation of SPN. For this reason, no
significant SPN activation, except a short-lived peak at the
rising shoulder of Meth concentration, was observed immedi-
ately after injection of the lower-intermediate dose in Fig. 3C.
The activity of SPN started to rise after the Meth concentration
in the blood fell enough to deactivate Inhib, but the concen-
tration transiently remained high enough to maintain Exc
activity. Accordingly, the duration of the latency period to
extended activation of the SPN was dose-dependent: the higher
the dose, the longer it takes to wash out Meth. Thus our model
suggests that, during the late phases of the responses, the SPN
population exhibits activity patterns identical to the precision
of the time shift, which monotonically increases with dose.
Temperature responses to higher-intermediate and high
doses. The maximal Meth concentration in the blood after the
higher-intermediate dose (5 mg/kg) was sufficient to slightly
activate the HD node (Fig. 4A, 3rd row of traces): 3.5 mg/kg
at maximum is in the very beginning of the HD step (3rd
vertical line in Fig. 3B). Accordingly, the activity of SPN
becomes bimodal: the first maximum was evoked by a slight
and immediate HD activation, and the second maximum was
mediated by a mechanism identical to the delayed response to
the 3 mg/kg dose, i.e., disinhibition of Mdl from Inhib during
Meth washout in the continued presence of Exc activity.
As the dose increased from 5 to 10 mg/kg, the HD compo-
nent was activated to a much greater extent (Fig. 3C). Inter-
estingly, although the magnitudes of the two components of the
excitatory drive (Exc and HD) are similar, activity of SPN was
threefold greater with HD activation than with similar Exc
activation, the effect of which was significantly attenuated by
the activation of the inhibitory drive. At high doses, the
inhibitory response was saturated and could not counteract
excessive thermogenesis.
Reduced Models
The model schematic shown in Fig. 3A (3-arrows model)
assumes that there are two distinct Meth-dependent excitatory
nodes, Exc and HD, with significantly different sensitivities,
that collectively determine the excitatory drive to the SPN
node. Together, they form a two-step response curve (solid line
in Fig. 4A), which can be treated as an activation curve of an
aggregate population composed of both nodes. This allows for
reduction of the model in such a way that two excitatory
Meth-sensitive nodes can be combined into a single node
characterized by a single sigmoidal activation curve (Fig. 4B).
We call such a reduced model the two-arrow model according
to the number of sites affected by Meth (Fig. 5A).
Two-arrow model. By elimination of the HD node from the
model schematic, the circuitry can be refigured as shown in
Fig. 5A to have only two Meth-sensitive nodes. In addition, this
allows combination of the Mdl and SPN nodes into a single
SPN node. With the optimal set of parameters (Table 1) and
corresponding activation curves for Meth-sensitive nodes (Fig.
5B), this two-arrow model also accurately reproduces the
observed data (Fig. 5C), predicting temperature responses
within 1 SD of the data for all times used for the fitting
procedure (220 min; vertical gray bars in Fig. 5C).
To place activation functions of Exc and Inhib nodes in the
context of effective concentrations of Meth, we have plotted
them (Fig. 4B), together with matching pharmacokinetic pro-
files (Fig. 4C). The response of the Exc node to Meth injections
does not saturate at the intermediate doses but, rather, contin-
ues to gradually increase as the dose increases. This results in
the monotonically increasing curve of the excitatory compo-
nent (solid line in Figs. 4B and Fig. 5B). The Inhib node, as in
the three-arrow model, has a sigmoidal activation function
(Fig. 5B).
In contrast to the three-arrow model, in the two-arrow
model, the activation curves of the Exc and Inhib nodes have
significantly different slopes (Figs. 4B and 5B, Table 1), which
results in a different mechanism of the Meth dose dependence.
After the lowest dose, SPN activity is increased by the excit-
atory drive, while the Inhib input barely reacts (Fig. 4B and
Fig. 4C, line 1). With increasing dose, the Inhib node abruptly
activates, the growth of inhibition prevails over a steady, but
moderate, increase in excitation, and the SPN becomes silent
(Fig. 4B and Fig. 4C, line 3). However, the inhibitory drive
eventually saturates, while the excitatory input to the SPN
continues to grow (Fig. 4B and Fig. 4C, lines 5 and 10), which
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results in activation of the SPN by sufficiently high doses of
Meth.
One-arrow model. In the two-arrow model, Exc and Inhib
populations are affected by Meth independently. However, one
can see that the entire range of Inhib sensitivity to Meth lies
within the linear Exc response (the entire “step” of the dashed
sigmoidal curve in Fig. 3B occurs while the solid curve is
gradually increasing). From a modeling perspective, this means
that we can leave only one Meth-sensitive input in the sche-
matic and replace individual Inhib sensitivity to Meth with the
excitatory input from Exc (Fig. 6A). Such a schematic is
supported by known excitatory projections from the DMH to
the RVLM (80).
At optimal parameter values (Table 1), this one-arrow model
produces population activation patterns indistinguishable from
those of the two-arrow model (compare Fig. 5C with Fig. 6B)
and accurately predicts experimental observations.
Temperature Variability in Response to Parameter
Variations
Experimental temperature curves exhibit significant animal-
to-animal variability. For instance, after injection of 10 mg/kg
Meth, the maximal temperature can differ by 2°C between
animals (see SDs in Fig. 1). To evoke similar alterations in the
model responses, we perturbed some model parameters relative
to their optimal values in Table 1. Specifically, we varied
synaptic weights of the projections from Exc and Inhib to Mdl
in the two- and three-arrow models and, additionally, from HD
to SPN in the three-arrow model, i.e., wExc¡Mdl, wInhib¡Mdl,
and wHD¡SPN. The increase in wExc¡Mdl and wHD¡SPN with a
corresponding decrease in wInhib¡Mdl produced the most exagger-
ated response, and a decrease in wExc¡Mdl and wHD¡SPN with an
increase in wInhib¡Mdl attenuated the response. Figure 7 shows
how a 3% change in the control parameters relative to their
optimal values altered the temperature curves produced by the
two- and three-arrow models. In both models, this change led
to temperature variations on the same order of magnitude as
experimentally observed variability (compare top and bottom
thick solid curves with error bars representing experimental
SDs in Fig. 7). Interestingly, such perturbations lead to notice-
ably greater temperature variations for the intermediate and
highest doses in the two-arrow than the three-arrow model.
Significant suppression of the inhibitory drive results in
dramatic amplification of Meth-induced hyperthermia (Fig. 8).
In the absence of inhibition, the response to 1 mg/kg Meth
approximately doubles, while a peak of the response to 3
mg/kg Meth exceeds 40°C and is close to life-threatening
levels. With inhibition suppressed by 50%, hyperthermia is not
so dramatic; however, after low Meth doses, body temperature
reaches levels typical for responses to high doses.
DISCUSSION
Meth-evoked hyperthermia alone can cause death, but it also
is known to aggravate neurological consequences of acute or
chronic use of amphetamines. Despite significant efforts to
determine reasons why some people develop life-threatening
hyperthermia while the thermal response of most people is not
a medical catastrophe, we do not have a clear idea of how
hyperthermia develops. In this study, we attempted to develop
an integrative model of temperature response to amphetamines,
in general, and to Meth, in particular.
Dose dependence of the temperature responses to Meth
appeared not to be trivial: intermediate doses (3 or 5 mg/kg;
Fig. 2) caused less hyperthermia than the lowest (1 mg/kg) and
highest (10 mg/kg) doses of Meth. Also, responses to the
lowest and highest doses were virtually instantaneous, while
responses to the intermediate doses were delayed. The highest
dose evokes profound hyperthermia followed by a second
temperature peak. Our results were qualitatively similar to
those described by Myles et al. (38).
Our approach to mathematical description of responses was
to model the involved neuronal circuitry in the form of an
1 mg/kg 3 mg/kg 5 mg/kg 10 mg/kg C 
 0 
 0.5 
 1 
 0 
 0.5 
 1 
 0 
 2 
 4 
 37 
 38 
 39 
 40 
E
xc
 (a
.u
.) 
In
hi
b 
(a
.u
.) 
S
P
N
 (°
C
) 
TE
M
P
 (°
C
) 
100 min 
A 
Exc SPN 
Inhib 
TEMP Meth 
Meth 
 0 
 0.2 
 0.4 
 0.6 
 0.8 
 1 
 0  2  4  6  8  10 
METH (mg/kg) 
Exc 
Inhib 
B 
Fig. 5. Two-arrow model. See Fig. 3 legend for details.
R559METH MATH
AJP-Regul Integr Comp Physiol • doi:10.1152/ajpregu.00365.2013 • www.ajpregu.org
 by 10.220.33.2 on Decem
ber 22, 2016
http://ajpregu.physiology.org/
D
ow
nloaded from
 
artificial neural network (1). Some of the nodes of the circuitry
putatively corresponded to actual neuronal populations in-
volved in thermoregulatory responses to amphetamines, in
accordance with current physiological conception. All model
parameters were chosen so that the model had the best fit to the
experimental time series. When we used the optimal set of
parameters, the simulated values of body temperature were
within 1 SD of actual experimental data throughout all time
courses for all doses (Table 3). Our model was additionally
validated by comparing the “best-fit” values of some measur-
able parameters with experimental values available from the
literature. For example, in all the models, Meth half-life in
plasma was estimated to be 1 h (or, more precisely, 57 min);
the same parameter in experimental studies was found to be
40–50 min (23) or 70 min (35).
More importantly, along with parameters that can be measured in
experimental settings with relative ease, we reconstructed the re-
sponses of the involved neuronal ensembles. Such an approach may
be a powerful tool for inferring the dynamics of individual functional
populations, since there are limited options for measuring neuronal
activity in conscious freely moving animals.
Mechanisms of Multimodal Responses in the Three-Arrow Model
Activities of the neuronal populations directly stimulated by
Meth ultimately converge at the SPN population, the activity of
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which is treated as the term responsible for thermogenesis in
Eq. 6. Increases in body temperature induced by Meth are
compensated by heat dissipation, which is proportional to the
difference from baseline body temperature: at baseline temper-
ature, non-Meth-induced heat generation and dissipation are at
equilibrium. For a specific Meth concentration in the blood, the
activity of SPN (see patterns in the 4th row of traces in Fig. 3C)
is defined by the difference between excitatory and inhibitory
components. The dependence of the excitatory and inhibitory
drives on Meth concentration in the blood (Fig. 4A) is shown
against pharmacokinetic profiles for all four doses (Fig. 4C).
The lowest dose of Meth (1 mg/kg) activates neither the
Inhib nor the HD node. Thermal output at this dose is depen-
dent on activity of a single multisynaptic pathway from the Exc
node through the Mdl to the SPN node. Activation of the Exc
node follows the Meth concentration in the blood, as does the
body temperature.
The increase to 3 mg/kg Meth is insufficient to activate SPN
through HD, but it exceeds the threshold of activation of the
inhibitory drive. Output of the Mdl is dependent on a balance
between excitatory and inhibitory drives: the difference be-
tween the dotted line and the dashed curve in Fig. 4A becomes
very small to the right from the second vertical line corre-
sponding to the 3 mg/kg dose. Before the inhibitory drive kicks
in, a short spike of supramedullary excitation (Fig. 3C) is
successfully transmitted through the Mdl during the absorption
phase, but this spike is very short and is not sufficient to cause
a noticeable change in body temperature.
In experimental settings, inhibition of the medullary relay
prevents downstream transmission of even maximal supramed-
ullary (hypothalamic) excitation (7, 9, 44, 63). This quite fits
our model data: the inhibitory drive successfully competes with
the supramedullary excitatory drive, so at the lower-interme-
diate dose, there is no immediate increase in body temperature.
Although the absence of an initial reaction may resemble a
delay of the response, it is, in fact, a result of competition
between two responses: excitatory and inhibitory.
Dose dependence of appearance of excitatory and inhibitory
components is of critical importance for interpretation of dose
dependence of responses to Meth. In a neuronal circuitry-based
model, excitatory and inhibitory components differ in sensitiv-
ity to Meth. Most likely, such a difference is due to the
predominant receptor mechanism responsible for the compo-
nent. Meth evokes release of multiple neuromediators, with ex-
citatory drive most likely mediated by dopamine (5, 28, 60). In
turn, the inhibitory component could have multiple origins in
monoaminergic systems, dopaminergic through D2 receptors (45),
adrenergic through 2-adrenoreceptors (34), or even serotonergic
through 5-HT1A receptors (55, 56). Inhibition could be actually
not direct but, rather, mediated by facilitation of the inhibitory
GABAergic drive, tonically present in this circuitry (26). The
variety of potentially involved mechanisms can explain differ-
ences of sensitivity of components of the model to Meth. Also, in
our modeling, we assumed uniform distribution of Meth, while
this assumption is not necessarily valid (33).
To discover specific mechanisms of physiological processes,
a modeling approach allows generation of testable hypotheses.
An assumption that the inhibitory drive is mediated by dopa-
mine or adrenoreceptors allows prediction of the dynamics of
the response to a specific dose of Meth under blockade of those
receptors (Fig. 8).
It is noteworthy that the intermediate doses result in a
sharp and very short-lived peak in Mdl/SPN activity at the
rising shoulder of the blood Meth concentration profile
before inhibition kicks in (Figs. 3, 5, and 6). This activation
is so short that, because of inertia of the thermal system (T
90 min), no significant increase in the body temperature
occurs. The presence of this short-lived initial peak pre-
dicted by all models could be the source of misinterpreta-
tions in neuroanatomic studies, if a marker of neuronal
activity such as c-fos immunoreactivity is used. Even though
the peak is too short to evoke a significant thermal response,
this short-duration (a few minutes) burst still could be
sufficient to induce c-fos expression. Once expressed, c-fos
is present in nuclei for a few hours (25). In such a situation,
the marker of neuronal activity will be present without a
clear physiological response.
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The higher-intermediate dose (5 mg/kg) did not activate HD
significantly, but for a short time the Meth level was elevated
enough to evoke a mild HD response. This drove a short-lived
activation of the SPN, which in turn resulted in a slight
increase in the body temperature seen in Fig. 2 immediately
after the injection. However, the HD-evoked activation does
not last long, so temperature does not further increase after the
initial rise.
Because of elimination, after the lower- and higher-
intermediate doses (3 and 5 mg/kg), blood levels of Meth
eventually drop below the threshold that is needed to main-
tain the inhibitory drive. However, these levels are still
sufficient to maintain the Exc activity that serves as an
excitatory drive for the Mdl. The latter, in turn, activates
SPN, which drives hyperthermia. Since e is significantly
greater than a (57 min vs. 8 min; Table 1), for t  a the
dynamics of the Meth concentration in the blood are defined
almost exclusively by elimination. By the time Meth con-
centration in the blood falls to levels at which the excitatory
input to the Mdl overcomes the inhibition, similar patterns
of body temperature are observed for all low and interme-
diate doses, because pharmacokinetics of Meth are similar
after this point. So the late phases of temperature responses
to intermediate doses are virtually identical to the response
to the lowest dose (see 1, 3 and 5 mg/kg in Fig. 2).
In contrast to the low and intermediate doses, the highest
dose activates HD significantly. In fact, our model suggests
that activation of HD provides remarkably stronger activation
of the SPN than the supramedullary component (Fig. 3C,
compare SPN activities at different doses). Interestingly, the
Exc alone provides input of similar magnitude (see Fig. 4A, 1st
step on the solid line), but it is significantly attenuated by its
inhibitory counterpart (Fig. 4A, dashed line). This makes the
slope of the temperature curve in the beginning of the response
greater at the highest dose than at the other doses.
Sustained Exposure to Meth
The suggested model can be used to estimate the maximal
body temperature that will be reached if thermogenic pathways
are activated to the utmost extent for a prolonged period of
time due to, for example, repeated Meth administration. The
excess of this steady-state temperature above the baseline
temperature (Eq. 6) is defined by the largest possible activity of
the SPN node, which can be estimated as the difference
between saturation levels of its excitatory and inhibitory inputs
(see solid and dashed lines in Fig. 4A for high Meth concen-
trations). This difference is 5°C, which implies a highest
possible temperature of 42°C. Evidently, high doses of Meth
are able to evoke life-threatening hyperthermia, even at ambi-
ent room temperature.
The hyperthermia evoked by low doses can be estimated in
a similar manner. If a low dose of Meth approximately equal to
1 mg/kg is maintained in the bloodstream for a long period of
time (repeated administration), the excess of the steady-state
temperature above the baseline will constitute 2°C (Fig. 4A),
which means an absolute body temperature of 39°C. This, by
itself, is not life-threatening but is definitely outside the normal
temperature range for healthy animals kept at room tempera-
ture.
Interestingly, our model predicts milder or even no hyper-
thermia for sustained intermediate concentrations of Meth,
since the excitatory input to SPN can be (completely) sup-
pressed by the inhibitory input for Meth concentration in the
blood of 2–3 mg/kg (solid and dashed lines almost coincide on
Fig. 4A in this range).
Simplified Model With Two Inputs for Meth
In the original three-arrow model, the Meth-sensitive nodes
are activated in a binary manner (Fig. 4A). They can be thought
of as triggers switched on and off as the Meth concentration in
the blood crosses its activation thresholds. The arrangement of
the thresholds (half-activation concentrations) defines a tem-
poral activation pattern of the network in response to a partic-
ular dose (Fig. 3, B and C, Table 1). Interestingly, the model
predicts comparable slopes of the activation curves for all three
Meth-sensitive nodes, wExc, wInhib, and wHD (Fig. 3B, Table 1).
The activation thresholds represent excitability of the corre-
sponding neuronal populations, which can be controlled by a
number of synaptic or intrinsic mechanisms.
A key feature of the model that defines the absence of a
thermogenic response when the intermediate doses of Meth are
maintained in the blood is that the activation curve of the Inhib
component (dashed line in Fig. 4A) touches the curve of the
Exc component (solid line in Fig. 4A). The same feature allows
for a different modeling solution implemented in the two-arrow
model (Fig. 4B). In this simplified model, we combined the
low-dose Exc and the high-dose HD components into a sin-
gle excitatory drive gradually activated throughout the entire range
of Meth variation (Figs. 5A and 4B). We also combined the
SPN with the Mdl into a single SPN node. In contrast to the
three-arrow model, where all doses of Meth activate the Exc
component to almost maximal values, in the simplified two-arrow
model, different doses of Meth activate the Exc component to a
different extent. Increasing the dose not only prolongs stimulation,
but it also increases the amplitude. At the same time, the activa-
tion curve of the Inhib component is similar to that in the
three-arrow model. Accordingly, after high doses, Inhib already
saturates, while the activity of Exc continues to grow with dose,
which creates an immediate “high-dose” component of hyperther-
mia (Fig. 4B and Fig. 4C, lines 5 and 10).
Model With a Single Input for Meth
As we mentioned above, the excitatory and inhibitory inputs
in the two-arrow model as functions of the Meth concentration
in the blood appear to have significantly different slopes (Figs.
4B and 5B). The inhibitory response curve is much steeper,
which makes the excitatory response curve virtually linear in
the corresponding range of Meth concentrations. Accordingly,
the response of the Inhib population to the changes in Meth
in the blood can be formed by the synaptic inputs from the Exc
and is not due to its intrinsic sensitivity to Meth (Fig. 6A). This
assumption, together with the assumption about actual neuro-
anatomic prototypes of the nodes of the model (Exc is the
DMH, Inhib is the RVLM), is supported by the existing
functional projections from the DMH to the RVLM (21, 80).
This one-arrow model represents an extreme case, when the
variety of possible temperature patterns is dictated by a specific
network organization, while the system receives a single Meth-
dependent input.
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Which Model Is Correct?
In this initial approach to develop a mathematical model of
temperature responses to amphetamines, we did not intend to
create an all-inclusive “ultimate” model of the circuitry in-
volved in those responses. We took this first step to break into
potential mechanisms defining nontrivial dose dependence of
responses to amphetamines. We showed that this complex
phenomenon can be explained by relatively simple neural
network architecture comprising a core of the temperature
control system.
We considered it important that we present various potential
circuitries that may underlie phenomena difficult to explain
using the qualitative approach typical of pharmacodynamics.
In our study, all three models replicated the experimental data
with comparable precision. However, each model can be used
to generate testable hypotheses for their subsequent experimen-
tal verification. One of the most obvious approaches to verify
the models may be inactivation or activation of the putative
anatomic structures involved in responses to Meth. For exam-
ple, we hypothesize that the supramedullary node is the DMH;
hence, the three-arrow model implies that inhibition of the
DMH should prevent responses to the lowest dose and will not
affect the initial phase of the response to the highest dose of
Meth but will suppress the late phase of responses to the
intermediate and highest doses.
Variability of Responses and Life-Threatening Hyperthermia
Our mathematical models can be used to gain insight into the
potential mechanism of life-threatening hyperthermia induced by
amphetamines. We found that a 3% change in certain parameters
is sufficient to significantly modify responses (Fig. 7).
The HD component is relatively short-lived: 60 min after
10 mg/kg, which defines the maximum of intense hyperther-
mia. Prolongation of this component would make the rising
shoulder after the high dose longer; therefore, body tempera-
ture will be able to reach life-threatening levels. Therefore,
dramatically greater responses to amphetamines could appear
due to purely pharmacokinetic, not pharmacodynamic, factors,
such as an increase in half-life or repeated administration.
Importantly, “low dose” is not showing its power only due to
prompt activation of the inhibitory drive. If not compensated
by the inhibitory drive, the effect of the excitatory drive after
low doses of Meth is comparable with the intensity of the
average “high-dose” component of the response. This predicts
that if, for any reason, the inhibitory drive is not activated by
Meth, even low doses of Meth will evoke a high-dose-like
response, with life-threatening levels of hyperthermia develop-
ing after “physiological” doses (Fig. 8). In the extreme situa-
tion, when no inhibitory drive is activated in the three-arrow
model, the calculations show that 3 mg/kg Meth will result in
a body temperature of 40.5°C in 100 min (Fig. 8). Catastrophic
consequences of inhibitory failure may be a plausible expla-
nation for a wide range of blood levels that can result in fatality
after amphetamine overdose (12): some cases could be due to
an actual overdose, while some could be due to an abnormal
response to relatively low doses.
Missing Parts of the Model/Future Directions
In any of these models, we did not include a component
associated with stress evoked by manipulations with an animal.
In fact, the disturbance caused by intraperitoneal injection
could significantly increase the body temperature of a con-
scious rat. The amplitude of the neuronal response to injection
could be comparable to the amplitude of the response to the
lowest dose of Meth, while usually it is significantly shorter.
Interestingly, slight hyperthermia due to the stress of injection
does not seem to appear at the intermediate doses (Fig. 1).
Pathways that are involved in the response to amphetamines
and stress are shared (58). With that in mind, it is quite logical
that activation of the inhibitory pathway will suppress the
excitatory drive induced by Meth and prevent stress-induced
hyperthermia. For simplicity, we did not include a stress
component in these studies; however, this is our plan for future
developments.
In our models, our use of T as a constant implies that no
thermoregulatory changes, such as cutaneous vasodilation,
occur in response to an increase in body temperature. In
experiments performed at room temperature, rats normally do
not thermoregulate through dissipation of heat. This mecha-
nism only activates when the body temperature increases above
a certain threshold (54). Activation of the sympathetic system
by Meth (59) offsets this control mechanism toward higher
thresholds, thus eliminating, or at least greatly attenuating, the
feedback involved in hyperthermia.
Feedback mechanisms are activated when conditions are
deviating from thermoneutrality; therefore, addition of feed-
back mechanisms to the model will be critical for proper
description of responses at extreme conditions, first, in hot or
cold environments. In such conditions, activity of already
functional feedback mechanisms could be modified by the
drug. For example, the amphetamine analog MDMA (ecstasy)
suppresses cold-induced thermogenesis (55). Fortunately, af-
ferent pathways and feedback mechanisms were extensively
modeled previously (18–20, 29, 30, 64, 73). However, addition
of such components to the model requires data obtained in
varying environmental conditions and was beyond the scope of
the current study.
When developing the model, we assumed that the medullary
node is the RP. It is known that, even at ambient room
temperature, inhibition of the RP results in a profound drop of
the body temperature (82), which implies that the RP normally
exhibits substantial tonic activity. The assimilation of such data
will allow introduction of additional constraints on the model
parameters.
It is known that administration of amphetamines results in
thermodysregulation: at elevated ambient temperatures, ani-
mals become hyperthermic, while at low ambient temperature,
they become hypothermic (60). This implies that pathways
involved in responses to amphetamines and changes in ambient
temperature are shared. However, inclusion of the ambient
temperature as an independent parameter into the model will
require formal description of thermoregulatory processes. We
consider this to be the next step in constructing a closed-loop
model of body temperature control, with the ultimate goal to
explain how Meth modulates/disrupts temperature regulation.
Conclusion
Our interdisciplinary experimental and modeling study re-
vealed that several relatively simple models are able to de-
scribe the complex pharmacodynamics of Meth. Our models
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had a few common features elucidating the essential mecha-
nisms of Meth-evoked hyperthermia. 1) The thermal outcome
is defined by the interaction of excitatory and inhibitory drives,
both of which are activated by Meth. 2) The low-dose-induced
component of the excitatory drive can be completely sup-
pressed by the inhibitory drive. Inadequate activation of the
Inhib component of the response to amphetamines may be the
reason for fatal hyperthermia. 3) The high dose of Meth
activates a component of the excitatory drive, which cannot be
compensated by the inhibitory drive, either because of its
location or insufficient strength of the Inhib component.
Perspectives and Significance
One of the most favorable outcomes of modeling is gener-
ation of a testable hypothesis. The common features of the
models described here are, in fact, such testable hypotheses.
While we developed the model with specific brain areas (e.g.,
DMH, RVLM, RP, and spinal cord) in mind, the actual
representation of nodes remains untested. To test our hypoth-
eses about involvement of the neuronal circuitry, it is necessary
to experimentally target the activity of the above-mentioned
neuronal populations. Also, the neuromediators involved in
synaptic transmission between these nodes are yet to be deter-
mined. We expect that targeted modulation of activity of
various brain structures and further pharmacological testing
will reveal the real faces of those schematic nodes and arrows.
The detailed model may provide a powerful tool for developing
new strategies and therapies against amphetamine-evoked life-
threatening hyperthermia.
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